Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer patients speak out: what they really want from pharmacy visits

NCT ID NCT05970471

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Besancon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study asked 167 people with cancer (and their caregivers) what they value most during pharmacy consultations for oral cancer drugs. Using a survey method, researchers identified key preferences to help hospitals design better support services. The goal was to improve patient education and safety, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

167 people

The number who actually took part.

Started

Aug 2023

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

240 patients - 60 Caregivers - 360 healhcare professionnals (pharmacist, oncologists, general practitioners)

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

of patients: Main inclusion Criteria: * Patients with lung, prostate breast, prostate or renal cancer; * Patients with oral cancer drugs; * Patients accepted to take par in pharmaceutical consultation in hospital.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm cancer colonic neoplasm kidney cancer lung cancer lung neoplasm neoplasm Patient Preference prostate cancer renal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer Caregiver Pharmacist-patient relations Preference, patient

Contacts and locations

Locations

  • CHU de Besançon

    Besançon, 25030, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.